DRD2 is critical for pancreatic cancer and promises pharmacological therapy by already established antagonists
DRD2 is critical for pancreatic cancer and promises pharmacological therapy by already established antagonists
批准号:
352306
负责人:
jandaghi Pouria
金额:
$0.07万
依托单位:
依托单位国家:
加拿大
项目类别:
财政年份:
2016
资助国家:
加拿大
项目状态:
已结题
起止时间:
2016-07-01 至 2016-08-01
中文摘要
点击翻译按钮获取中文摘要
英文摘要
For pancreatic cancer, the rate of diagnosis is almost similar to the rate of mortality because in majority of patients, tumor is discovered in the late stages when it has spread throughout the pancreas. This aggressive behavior of pancreatic cancer gives
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Growth inhibitory and chemo-sensitization effects of DRD2 antagonism in pancreatic cancer
-
批准号:391486
-
项目类别:
-
资助金额:$0.09万
-
财政年份:2018
-
负责人:jandaghi Pouria
-
依托单位:
海外基金